Brief: Oncocyte Announces Publication Of Validation Of Determaio In Predicting Immune Therapy Response In Metastatic Bladder Cancer
24/08/2022 13:08
Aug 24 (Reuters) - OncoCyte Corp OCX.O :
* ONCOCYTE ANNOUNCES PUBLICATION OF THE VALIDATION OF
DETERMAIO IN
PREDICTING IMMUNE THERAPY RESPONSE IN METASTATIC BLADDER CANCER
Source text for Eikon: ID:nGNX7P5Dl1
Further company coverage: OCX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insight Molecular Diagnostics
See all newsBrief: Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a share - Earnings Preview
Insight Molecular Diagnostics Q1 loss narrows as costs drop
Brief: Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission